Maze Therapeutics Inc [MAZE] stock is trading at $42.6, up 2.68%. An important factor to consider is whether the stock is rising or falling in short-term value. The MAZE shares have gain 12.11% over the last week, with a monthly amount glided 31.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maze Therapeutics Inc [NASDAQ: MAZE] stock has seen the most recent analyst activity on December 04, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $55. On September 02, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $30 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $34 on July 23, 2025. Wedbush initiated its recommendation with an Outperform and recommended $17 as its price target on July 08, 2025.
Maze Therapeutics Inc [MAZE] stock has fluctuated between $6.71 and $41.88 over the past year. Currently, Wall Street analysts expect the stock to reach $40.67 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $42.6 at the most recent close of the market. An investor can expect a potential drop of -4.53% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
Maze Therapeutics Inc [NASDAQ:MAZE] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.45 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.23 points at the first support level, and at 39.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.63, and for the 2nd resistance point, it is at 44.66.
Ratios To Look Out For
For context, Maze Therapeutics Inc’s Current Ratio is 17.70. On the other hand, the Quick Ratio is 17.70, and the Cash Ratio is 14.33.
Transactions by insiders
Recent insider trading involved SEKAR KATHIRESAN, Former Board Member, that happened on Dec 04 ’25 when 10000.0 shares were purchased. Former Board Member, SEKAR KATHIRESAN completed a deal on Nov 21 ’25 to buy 27500.0 shares. Meanwhile, Director SCHELLER RICHARD H sold 20744.0 shares on Sep 15 ’25.
